Table 1.
Overall in vivo transmission-blockade following immunization with PbPfs25DR3 ookinetes by DFA.
| Regime | Total mice | Total mosquitoes | Mean oocyst intensity (±SEM) | Mean infection prevalence | Mean reduction in intensity | Mean reduction in prevalence |
|---|---|---|---|---|---|---|
| 1: PbPfs25DR3 Alhydrogel – 1 boost | 5 | 250 | 41.96 (5.6) | 83.2% | −17.4% | −4.1% |
| 2: PbPfs25DR3 Matrix M – 1 boost | 5 | 250 | 7.56 (1.1) | 48.4% | 85.7%*** | 39.3%*** |
| 3: PbPfs25DR3 Alhydrogel – 2 boost | 5 | 199 | 29.53 (3.8) | 85% | 12.8% | −6.3% |
| 4: PbPfs25DR3 Matrix M – 2 boost | 5 | 250 | 3.82 (0.7) | 50% | 93.3%*** | 50.6%*** |
| 5: ChAd63-Pfs25/PbPfs25DR3 Alhydrogel | 4 | 200 | 20.14 (3.3) | 62.5% | 55.7%*** | 19.6%*** |
| 6: ChAd63-Pfs25/PbPfs25DR3 Matrix M | 4 | 200 | 7.1 (1.3) | 42.5% | 86.5%*** | 48.2%** |
| 7: WT 2.34 Alhydrogel – 1 boost | 5 | 77 | 35.41 (8.3) | 87.6% | −5.3% | −5.4% |
| 8: WT 2.34 Matrix M – 1 boost | 5 | 250 | 24 (3.1) | 79.2% | 38.9% | −0.2% |
| 9: WT 2.34 Alhydrogel – 2 boost | 5 | 227 | 25.8 (3.3) | 80.1% | 24.1% | −0.2% |
| 10: WT 2.34 Matrix M – 2 boost | 5 | 250 | 12.01 (1.9) | 75.6% | 66.1%* | 4.2% |
| 11: ChAd63-GFP/ WT 2.34 Alhydrogel | 5 | 230 | 44.5 (5.5) | 91.6% | −33.2% | −14.9% |
| 12: ChAd63-GFP/ WT 2.34 Matrix M | 5 | 250 | 37.6 (5.1) | 83.6% | −10.6% | −5.2% |